Infection Watch

Time for the next consensus meeting on orthopedic infections

It has been 5 years since the first International Consensus Meeting on Periprosthetic Joint Infection was held. That meeting, held in Philadelphia, was lauded as a success and was attended by 400 delegates from 52 countries. The proceedings of the meeting were published in the peer-reviewed Journal of Arthroplasty and in a book translated into 18 languages that came out after the meeting. More than 30,000 copies of the book were distributed worldwide. The definition of periprosthetic joint infection proposed by the International Consensus Meeting group was adopted by the CDC.

The incidence of surgical site infection (SSI) following orthopedic procedures continues to increase, threatening the ultimate success of the procedures we perform and potentially posing a threat to our profession.

Javad Parvizi, MD, FRCS

Javad Parvizi

The orthopedic community continues to engage in research and generate evidence in this area. Despite these efforts, numerous aspects of patient care still lack conclusive evidence with regard to SSI, which poses a challenge to clinicians who treat patients with orthopedic infections. In fact, this issue was also identified by the CDC when it recently updated its SSI prevention guidelines.

The time has come to gather again and determine what we know, what we do not know and what we need to do to know more. The Second International Consensus Meeting (ICM) on Musculoskeletal Infection will be held July 25-27, 2018, in Philadelphia. Meeting organizers have identified more than 700 delegates from 102 countries who have agreed to serve at the upcoming meeting.

The Second ICM on Musculoskeletal Infection will differ from the first meeting held in 2013. It will involve delegates from orthopedic subspecialties in spine, trauma, foot and ankle, shoulder and elbow, oncology, pediatrics and sports.

This year, the consensus will again be conducted according to the Delphi method. Attendees will participate in 18 workgroups to evaluate the available literature, extract evidence for current practice and identify areas in need of further research. This time, however, the level of evidence related to each “recommendation” will be determined and highlighted. No published work related to orthopedic infection will be missed.

This year’s meeting will also allow for the participation of representatives from government organizations, payers and business administration. Although these participants will not be allowed to vote during the consensus process, their participation is important for developing the road map for funding, supporting and approving technologies related to orthopedic infection in the future.

The objective of this meeting is to convene renowned, international experts in orthopedic infection from more than 80 countries and 200 orthopedic societies to develop a document that can be used to improve the care of our patients afflicted with musculoskeletal infection.

Disclosure: Parvizi reports he is a paid consultant for Zimmer Biomet, ConvaTec, TissueGene, CeramTec and Ethicon; has stock options with Parvizi Surgical Innovations, Hip Innovation Technology, CD Diagnostics, CorenTec, Alphaeon, Joint Purification Systems, Ceribell, MedAp, MicroGenDx, Cross Current Business Intelligence, Invisible Sentinel, Physician Recommended Nutriceuticals and Intellijoint; and receives royalties from CorenTec, Datatrace, Elsevier, Jaypee, SLACK Incorporated and Wolters Kluwer.

It has been 5 years since the first International Consensus Meeting on Periprosthetic Joint Infection was held. That meeting, held in Philadelphia, was lauded as a success and was attended by 400 delegates from 52 countries. The proceedings of the meeting were published in the peer-reviewed Journal of Arthroplasty and in a book translated into 18 languages that came out after the meeting. More than 30,000 copies of the book were distributed worldwide. The definition of periprosthetic joint infection proposed by the International Consensus Meeting group was adopted by the CDC.

The incidence of surgical site infection (SSI) following orthopedic procedures continues to increase, threatening the ultimate success of the procedures we perform and potentially posing a threat to our profession.

Javad Parvizi, MD, FRCS

Javad Parvizi

The orthopedic community continues to engage in research and generate evidence in this area. Despite these efforts, numerous aspects of patient care still lack conclusive evidence with regard to SSI, which poses a challenge to clinicians who treat patients with orthopedic infections. In fact, this issue was also identified by the CDC when it recently updated its SSI prevention guidelines.

The time has come to gather again and determine what we know, what we do not know and what we need to do to know more. The Second International Consensus Meeting (ICM) on Musculoskeletal Infection will be held July 25-27, 2018, in Philadelphia. Meeting organizers have identified more than 700 delegates from 102 countries who have agreed to serve at the upcoming meeting.

The Second ICM on Musculoskeletal Infection will differ from the first meeting held in 2013. It will involve delegates from orthopedic subspecialties in spine, trauma, foot and ankle, shoulder and elbow, oncology, pediatrics and sports.

This year, the consensus will again be conducted according to the Delphi method. Attendees will participate in 18 workgroups to evaluate the available literature, extract evidence for current practice and identify areas in need of further research. This time, however, the level of evidence related to each “recommendation” will be determined and highlighted. No published work related to orthopedic infection will be missed.

This year’s meeting will also allow for the participation of representatives from government organizations, payers and business administration. Although these participants will not be allowed to vote during the consensus process, their participation is important for developing the road map for funding, supporting and approving technologies related to orthopedic infection in the future.

The objective of this meeting is to convene renowned, international experts in orthopedic infection from more than 80 countries and 200 orthopedic societies to develop a document that can be used to improve the care of our patients afflicted with musculoskeletal infection.

Disclosure: Parvizi reports he is a paid consultant for Zimmer Biomet, ConvaTec, TissueGene, CeramTec and Ethicon; has stock options with Parvizi Surgical Innovations, Hip Innovation Technology, CD Diagnostics, CorenTec, Alphaeon, Joint Purification Systems, Ceribell, MedAp, MicroGenDx, Cross Current Business Intelligence, Invisible Sentinel, Physician Recommended Nutriceuticals and Intellijoint; and receives royalties from CorenTec, Datatrace, Elsevier, Jaypee, SLACK Incorporated and Wolters Kluwer.